Uses of Adorucin

Adorucin drug is used in the treatment of cancer such as: lung cancer, breast cancer, myeloma, bladder cancer, ... The drug has the main ingredient is Doxorubicin hydrochloride. Let's find out more details about the uses, usage and notes when using Adorucin through the following article.

Adorucin belongs to the group of anti-cancer drugs and affects the immune system, which is made in the form of a clear red injectable solution packed in a box of 1 colorless 5ml vial.
Adorucin drug includes the main ingredient Doxorubicin hydrochloride 10mg/5ml and other excipients such as sodium chloride, hydrochloric acid, purified water.

Adorucin is used in the treatment of cancers, specifically the following cases:
SCLC lung cancer. Breast cancer. Ovarian carcinoma. Bladder cancer. Support and treatment of malignant bone tumors. Soft tissue sarcoma in adults. Sarcom Ewing. Malignant lymphomas include Hodgkin's and non-Hodgkin's. Acute lymphocytic leukemia. Acute myeloid leukemia. Progressive multiple myeloma. Progression or recurrence of endometrial cancer. U Wilm. Follicular thyroid cancer or papillary thyroid cancer. Undifferentiated thyroid cancer. Neuroblastoma. Stomach cancer is metastatic. Adorucin is often used in chemotherapy regimens in combination with other cytotoxic drugs.

Adorucin is used intravenously as a drip for 2-3 minutes, helping to minimize the risk of blood clots or the drug escaping into the vein causing swelling and severe necrosis.
Dosage of Adorucin refer to the following:
Calculation by skin charge: When using only Adorucin, the dose is 60-75 mg Doxorubicin/m2 of skin area, 3 weeks apart. If used in combination with other chemotherapeutic agents with similar toxicity, the dose may need to be reduced by 30-40 mg of Doxorubicin/m2 of skin, spaced 3 weeks apart.
By weight: It has been reported that a single dose of Adorucin every 3 weeks significantly reduces mucositis and pain toxicity. However, it is also reported that divided doses of Adorucin for 3 consecutive days (0.4 - 0.8 mg Doxorubicin/kg or 20 - 25 mg Doxorubicin/m2 daily) would be more effective, although higher toxicity. If Doxorubicin is used in combination with other chemotherapeutic agents with the same toxicity, the dose of Adorucin may need to be reduced by 30-40 mg Doxorubicin/m2 of skin, spaced 3 weeks apart
For patients with impaired liver function, The dose of Adorucin is as follows:
Serum bilirubin concentration 1.2-3.0 mg/100mL: The recommended dose is 50% of the normal dose. Serum bilirubin >3.0 mg/100mL: The recommended dose is 25% of the normal dose. In the therapeutic dose should not exceed the recommended dose of 550mg/m2 skin area. Adorucin should be given slowly through an intravenous line of sodium chloride infusion, or 5% dextrose infusion. The rate of infusion of Adorucin depends on the dose administered and the size of the vein. If the patient develops a flushed face or an erythema along the veins, the infusion rate is too fast. If there is pain or burning at the injection site, which means that the drug has escaped from the vessel wall, the Adorucin infusion must be stopped immediately and another vein should be found. There are also cases where the drug Adorucin escapes from the vessel wall without causing any pain. Do not mix Adorucin with heparin or other drugs.
Adorucin is not intended for intramuscular and subcutaneous administration. Do not use Adorucin intraperitoneally due to the risk of intestinal obstruction. Because intravenous use can cause phlebitis, vasculitis, embolism, should pay attention to the injection site and technique, inject as slowly as possible.

Adorucin should not be used in the following cases:
Patients with hypersensitivity to Doxorubicin or to any of its ingredients. Pregnant and breastfeeding. Contraindications when using doxorubicin intravenously:
Patients sensitive to Anthracyclines or Anthracendion. Patients present with persistent bone marrow depression or severe stomatitis caused by previous treatment with other cytotoxic drugs or irradiation. Prior treatment with the maximum cumulative dose of Doxorubicin or other anthracyclines such as Daunorubicin, Epirubicin, Idarubicin, and Anthracyclines. Systemic infection. Severe liver failure. Heart failure, severe arrhythmia, previous myocardial infarction, acute inflammatory heart disease. Tendency to increase bleeding. Breastfeeding women. Contraindications when using Adorucin in the bladder:
Tumors invading the bladder. Cystitis. Blood in urine. Difficulty instituting a urinary catheter. Breastfeeding women. Urinary tract infections. Patients with AIDS-associated Kaposi cancer are effectively treated with alpha-interferon systemic or topical therapy.

Below are some drug lines when combined with Adorucin can occur drug interactions such as:
Drugs that inhibit bone marrow reproduction Drugs with hepatotoxicity. Cyclosporin. Digoxin. Doxorubicin should not be taken with lye or heparin solutions. Other anticancer drugs. Co-administration of doxorubicin may increase the potential for hemorrhagic cystitis of cyclophosphamide and increase the hepatotoxicity of 6-mercaptopurine. The combination of Doxorubicin and radiation therapy increases radiation toxicity such as mucositis and skin reactions. Propranolol taken with Doxorubicin will increase cardiotoxicity.

During the use of Adorucin, patients may experience some side effects as follows:
Heart: Tachycardia, ventricular tachycardia, arrhythmia, changes in the electrocardiogram. Patients need to be monitored electrocardiogram when treating, especially for patients with heart failure. Shock (rarely). Patients should be closely monitored, if necessary, stop taking Adorucin and institute appropriate treatment. Blood: Bleeding, anemia, leukopenia, and thrombocytopenia. Hypersensitivity reactions: Urticaria, fever, chills, anaphylaxis may occur. Liver: Impaired liver function (Uncommon) Kidney: Proteinuria. Gastrointestinal: Nausea and vomiting, gastritis and esophagitis, anorexia, diarrhea have occasionally been reported. Skin: Hair loss, darkening of the nails and wrinkling of the skin that are reversible upon discontinuation of treatment occur in most cases. Central nervous system: Headache, fatigue, somnolence Urinary system: Cystitis, oliguria, hematuria may occur during bladder pump therapy. Other undesirable effects: No sperm, missed menstruation.
Patients should inform the doctor, pharmacist of the unwanted effects encountered when using Adorucin.

Adorucin should only be used under the supervision of a physician with sufficient experience in the treatment of cytotoxic intravenous or bladder administration. Doxorubicin may increase the toxicity of other anticancer therapies. Careful management of clinical complications should be exercised, particularly in elderly patients, in patients with a history of cardiac disease or with bone marrow suppression, or in patients previously treated with derivatives. anthracyclines or treated with radiation to the mediastinum.
Close observation of the patient's condition and monitoring of general trials is required during initial treatment. Therefore, it is recommended that patients be hospitalized at least during the initial phase of treatment. Doxorubicin can cause infertility while taking the drug.
If the patient has neutropenia, thrombocytopenia, stomatitis, and systemic infection, the acute toxicity of previous treatment should be reversed before starting treatment with Doxorubicin.
During treatment with Adorucin, the patient should check the following tests as recommended:
Chest and lung X-ray Do electrocardiogram (ECG). Closely and regularly monitor cardiac function: left ventricular ejection fraction (LVEF) by UCG, ECG and MUGA scan. Check the oral cavity and pharynx daily for mucosal changes. Blood tests: platelets, hematocrit, leukocyte differentiation, uric acid, SGPT, SGOT, LDH, bilirubin. Hopefully, the sharing about Adorucin drug will help patients know how to use the drug to achieve the best and safest treatment effect for their health. If you have any questions about medication use, you should contact your doctor for in-depth advice.